Shay Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Shay Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-45,000	Closed	-$742K	–	365
2023 Q2	$742K	Buy	+45,000	New	+$585K	0.1%	124

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital's AVDL Position: Q1 2025 in Review

Shay Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 20,381 shares — an estimated $214K sold.

Shay Capital first reported a position in AVDL in Q2 2023 and held it in 5 quarters. The position peaked at $1.09M in Q2 2023. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

Shay Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Shay Capital sold 20,381 Avadel Pharmaceuticals shares in Q1 2025, an estimated $214K.
Shay Capital first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 5 quarters.
Shay Capital's Avadel Pharmaceuticals position peaked at $1.09M in Q2 2023.
175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.